Edesa Biotech CEO Pardeep Nijhawan Receives 96,913 Restricted Share Units

This Form 4 filing reports that Pardeep Nijhawan, CEO, Director, and 10% owner of Edesa Biotech, Inc., received 96,913 restricted share units on May 27, 2026. The grant was made under the company's 2019 Equity Incentive Compensation Plan and will vest monthly over 36 months starting from the grant date. The transaction price was $0 per share, indicating an equity compensation grant rather than a market purchase. Following this transaction, Nijhawan's direct ownership increased to 729,463 common shares. Additionally, he has indirect ownership through several entities: 402,702 shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,609 shares held by The New Nijhawan Family Trust 2015, 32,013 shares held by The Digestive Health Clinic Inc., and 53,104 shares held by 1968160 Ontario Inc. The filing includes disclaimers regarding beneficial ownership of shares held by these entities, with Nijhawan stating he disclaims beneficial ownership except to the extent of his pecuniary interest.